Tirzepatide Dosage: Amounts Used in Studies
How tirzepatide amounts rose in studies
Drug makers tested a slow 4-week rise. They hoped more time would ease stomach and bowel trouble. The diabetes studies called SURPASS and weight studies called SURMOUNT used this plan. It doesn’t set an amount for you.
— The starting study amount was 2.5 mg each week for 4 weeks. — It then rose to 5 mg each week for 4 weeks. — The next step was 10 mg each week for 4 weeks. — The highest amount studied was 15 mg each week.
They’re the long-term study amounts: 5 mg, 10 mg, and 15 mg in a shot under the skin. People who couldn’t handle the next step stayed at the last amount they could take. Most people in SURPASS-1 through SURPASS-5 reached and stayed at 15 mg [2][4][5].
By week 8 in SURPASS-1, the average-sugar blood test was clearly lower. Weight differed from placebo within 4 weeks in SURMOUNT-1 [2][6]. Neither study says when you might notice a change. I’d ask when the clinic will check you and what could change the plan.
How long tirzepatide stayed in the body
Researchers found that the body cleared half the tirzepatide in about 5 days. The average was 5.4 days across 19 studies, and estimates stayed near 5 days [18]. That’s why the studies used weekly shots.
After about 4 weeks, the shots built to a steady amount in the blood. That usually took 4 to 5 doses. In 32 people, healthy and weak livers handled the drug in about the same way [18][19]. The study wasn’t large, so your clinician still has to judge your health.
Your body breaks tirzepatide into small pieces, then gets rid of them through urine and stool. The kidneys and liver weren’t the main parts doing that work. Age, sex, race, and body weight didn’t greatly change the timing. About 5 days passed before half was gone. These are group findings, not one person’s result.
Researchers didn’t change study amounts just for those traits [18]. That group rule can’t replace a clinician who knows you. A fatty part of tirzepatide holds to the blood protein albumin. That’s how the drug lasts through a weekly study plan.
How and where studies gave tirzepatide shots
Tirzepatide injection route in all phase-3 clinical trials: subcutaneous injection, administered once weekly. Approved injection sites in the clinical protocols included the abdomen, thigh, and upper arm. Intravenous administration was studied in dedicated pharmacokinetic studies only.
Injection-site reactions were reported as adverse events in the SURPASS and SURMOUNT programs but at low rates. The most common injection-site findings were mild erythema and transient injection-site pain. No signal of lipodystrophy or clinically significant injection-site pathology was documented in the primary trial publications [14][15].
Dose units: tirzepatide is dosed in milligrams (mg), not micrograms or international units. The dose-escalation schedule runs from 2.5 mg to a maximum of 15 mg per injection. Each injection is administered on the same day each week; the day of the week may be changed if the minimum interval of 72 hours between injections is maintained [16].
The distinction between protocol reporting and personal care is material: Tirzepatide schedules in the published record describe study design, while prescription-only access proceeds through a licensed, clinician-led route such as Promise Peptides (mypromise.com), with suitability assessed individually rather than copied from a trial arm.
For tirzepatide dosage studied in clinical trials detail, including the full dose-escalation table and endpoint outcomes by dose arm, refer to the protocol sections on this page. For tirzepatide side effects related to injection, including injection-site reactions and GI tolerability data, see the side effects log.
What kept tirzepatide pens and lab powder usable
The approved prefilled tirzepatide pen and dry lab powder aren’t the same thing. A pen stayed at 2-8 degrees celsius, the cold range in a refrigerator, for a 24-month shelf life [16]. Dry research powder isn’t a home supply. Work on similar GLP-1 drugs used -20 degrees celsius, a lab freezer setting, for 24 months or more, away from light and moisture [18].
Lab directions also kept dry GLP-1 samples at -20 degrees celsius. Workers used sterile water, which limits germs, when mixing the powder. The mixed liquid stayed at 2-8 degrees celsius, in refrigerator cold, and away from light. Similar drugs lasted 28 to 56 days under those lab rules [18].
Those figures don’t give compounded tirzepatide one shelf life. The -20 degrees celsius figure is for dry lab powder. The 2-8 degrees celsius figure is for cold liquid. Air, water, or clumping can harm the fatty part of the drug [18].
For a prescription, ask the pharmacy for the exact label. Ask when your supply was mixed and when to throw it away. A lab note isn’t home care advice. That’s the date on your own label that matters.